These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 579063)

  • 41. Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol.
    Asper H; Baggiolini M; Burki HR; Lauener H; Ruch W; Stille G
    Eur J Pharmacol; 1973 Jun; 22(3):287-94. PubMed ID: 4738903
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug.
    Uchida S; Honda F; Otsuka M; Satoh Y; Mori J; Ono T; Hitomi M
    Arzneimittelforschung; 1979; 29(10):1588-94. PubMed ID: 42413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bromoperidol, a new potent neuroleptic of the butyrophenone series. Comparative pharmacology of bromoperidol and haloperidol.
    Niemegeers CJ; Janssen PA
    Arzneimittelforschung; 1974 Jan; 24(1):45-52. PubMed ID: 4406109
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
    Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
    Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
    [No Abstract]   [Full Text] [Related]  

  • 45. [Behavior pharmacology of maprotiline, a new antidepressant].
    Ueki S; Fujiwara M; Inoue K; Kataoka Y; Ibii N
    Nihon Yakurigaku Zasshi; 1975 Nov; 71(8):789-815. PubMed ID: 1240830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemical and pharmacological classification of neuroleptics.
    Janssen PA
    Mod Probl Pharmacopsychiatry; 1970; 5():33-44. PubMed ID: 5535847
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 4. Central nervous system depressants.
    Allen RC; Bauer VJ; Kosley RW; McFadden AR; Shutske GM; Cornfeldt ML; Fielding S; Geyer HM; Wilker JC
    J Med Chem; 1978 Nov; 21(11):1149-54. PubMed ID: 31478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical and pharmacological differentiation of neuroleptic effect on dopamine D-1 and D-2 receptors.
    Hyttel J; Christensen AV
    J Neural Transm Suppl; 1983; 18():157-64. PubMed ID: 6135740
    [TBL] [Abstract][Full Text] [Related]  

  • 51. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.
    Millan MJ; Dekeyne A; Rivet JM; Dubuffet T; Lavielle G; Brocco M
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1063-73. PubMed ID: 10869411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
    Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological properties of substituted gamma-butyrolactones. I. The effects on the central nervous system.
    Sieroslawska J; Hano J; Sypniewska M; Czarnecki R; Chojnacka-Wójcik E; Harasiewicz A
    Pol J Pharmacol Pharm; 1973; 25(1):1-16. PubMed ID: 4798097
    [No Abstract]   [Full Text] [Related]  

  • 54. Inhibition of amphetamine- and apomorphine-induced behavioural effects by neuropeptide Y Y(1) receptor antagonist BIBO 3304.
    Kask A; Harro J
    Neuropharmacology; 2000 Apr; 39(7):1292-302. PubMed ID: 10760371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
    Akhtar M; Uma Devi P; Ali A; Pillai KK; Vohora D
    Fundam Clin Pharmacol; 2006 Aug; 20(4):373-8. PubMed ID: 16867021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sensitization of mice to methylphenidate.
    Shuster L; Hudson J; Anton M; Righi D
    Psychopharmacology (Berl); 1982; 77(1):31-6. PubMed ID: 6812116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The interaction of clonidine with dopamine-dependent behaviour in rodents.
    Pycock CJ; Jenner PG; Marsden CD
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Mar; 297(2):133-41. PubMed ID: 558529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological properties of a new potential neuroleptic drug oxyprothepin. IV. Antiadrenergic action and influence on brain monoamines.
    Dlabac A; Metys J; Metysová J
    Act Nerv Super (Praha); 1971; 13(3):188-9. PubMed ID: 5113833
    [No Abstract]   [Full Text] [Related]  

  • 59. A comparison of narcotic analgesics with neuroleptics on behavioral measures of dopaminergic activity.
    Lal H; Gianutsos G; Puri SK
    Life Sci; 1975 Jul; 17(1):29-34. PubMed ID: 238089
    [No Abstract]   [Full Text] [Related]  

  • 60. Substituted benzamides as cerebral dopamine antagonists in rodents.
    Elliott PN; Jenner P; Huizing G; Marsden CD; Miller R
    Neuropharmacology; 1977 May; 16(5):333-42. PubMed ID: 559256
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.